Literature DB >> 21167541

Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma.

Shou-Wang Cai1, Shi-Zhong Yang, Jie Gao, Ke Pan, Ji-Ye Chen, Yu-Lan Wang, Li-Xin Wei, Jia-Hong Dong.   

Abstract

BACKGROUND: Recently, there is evidence that the number of mast cells in various solid cancers increases with tumor progression. The role of mast cells in promoting tumor progression, however, has not been well studied in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to investigate the prognostic value of mast cell counts in different zones of the neoplasm in patients with PDAC after curative resection.
METHODS: Numbers of mast cells and microvessels were assessed by immunohistochemistry in tissues from 103 patients with PDAC and 10 patients with normal pancreas. All patients with PDAC underwent partial pancreatic resection. The investigators paid particular attention to the distribution of mast cells in each specimen.
RESULTS: High mast cell counts in the intratumoral border zone correlated with the presence of lymphatic and microvascular invasion, lymph node metastasis, and TNM stage, and were an independent prognostic factor for overall survival (P < .001). In contrast, neither in the intratumoral center zone nor in the peritumoral zones was mast cell count associated with OS. Mast cell counts in the intratumoral border zone, but not in the peritumoral or in the intratumoral center zone, were correlated with microvessel counts.
CONCLUSION: The present study shows a zone-specific distribution of mast cells in PDAC and highlights the importance of invasive front in the prognosis of patients with PDAC after curative resection. Zone-specific evaluation of mast cell and microvessel counts may be helpful for prognostic assessment and therapeutic decision making in PDAC.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21167541     DOI: 10.1016/j.surg.2010.10.009

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  41 in total

1.  Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Authors:  Daniel Massó-Vallés; Toni Jauset; Erika Serrano; Nicole M Sodir; Kim Pedersen; Nesrine I Affara; Jonathan R Whitfield; Marie-Eve Beaulieu; Gerard I Evan; Laurence Elias; Joaquín Arribas; Laura Soucek
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

Review 2.  Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.

Authors:  Lei Zheng; Jing Xue; Elizabeth M Jaffee; Aida Habtezion
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

3.  Impact of Intratumoral Inflammation on Survival After Pancreatic Cancer Resection.

Authors:  Phil A Hart; Thomas C Smyrk; William R Bamlet; Suresh T Chari
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327

4.  mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.

Authors:  Daniel Smrz; Mi-Sun Kim; Shuling Zhang; Beverly A Mock; Sárka Smrzová; Wendy DuBois; Olga Simakova; Irina Maric; Todd M Wilson; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

Review 5.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

Review 6.  Mast cells and angiogenesis in pancreatic ductal adenocarcinoma.

Authors:  Vito Longo; Roberto Tamma; Oronzo Brunetti; Salvatore Pisconti; Antonella Argentiero; Nicola Silvestris; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2018-02-28       Impact factor: 3.984

Review 7.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

Review 8.  Inflammation and pancreatic cancer: disease promoter and new therapeutic target.

Authors:  Shin Hamada; Atsushi Masamune; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2013-11-30       Impact factor: 7.527

Review 9.  Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.

Authors:  Michael Friberg Bruun Nielsen; Michael Bau Mortensen; Sönke Detlefsen
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 10.  Complex role for the immune system in initiation and progression of pancreatic cancer.

Authors:  Kristin S Inman; Amanda A Francis; Nicole R Murray
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.